Clinical and Translational Oncology

, Volume 10, Issue 11, pp 688–696

Langerhans cell histiocytosis


    • Hospital General Universitari Marina Alta
  • Vicente Alberola Candel
    • Hospital Universitari Arnau de Vilanova
  • Carlos Solano Vercet
    • Hospital Clinic Universitari
  • Juan Laforga Canales
    • Hospital General Universitari Marina Alta
  • Christof Semler
    • Centro Clínico Euroclínica Jàvea
  • M. Rosa Pérez Antolí
    • Centro Clínico Euroclínica Jàvea
  • Carlos Rodríguez-Galindo
    • Department of OncologySt Jude Children’s Research Hospital
Educational Series

DOI: 10.1007/s12094-008-0275-9

Cite this article as:
Gasent Blesa, J.M., Alberola Candel, V., Vercet, C.S. et al. Clin Transl Oncol (2008) 10: 688. doi:10.1007/s12094-008-0275-9


Langerhans cell histiocytosis (LCH) is a poorly understood proliferative disease, with different patterns of clinical presentation. Currently it is classified according to the number and type of system involved and the degree of organ dysfunction. The aetiology of the disease remains uncertain, and in some cases the disease is polyclonal, suggesting a reactive condition. Many cytokines have been implicated in the pathogenesis of LCH. Different therapeutic approaches can be considered depending on the affected organ, including surgery, radiotherapy and chemotherapy. Long-term organ dysfunction may remain, despite disease control and/or eradication, making indefinite supportive treatment mandatory. Here we present a literature review on all of the aspects of the disease, treatment approaches and existing protocols, and finally an adult clinical case.


Langerhans’s cell histiocytosisAdultReview

Copyright information

© Feseo 2008